Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2016 from OUS - Department of Molecular Oncology (2006-2014 Dept of Cancer Prev.)
25 publications found
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Nat Rev Gastroenterol Hepatol, 13 (5), 261-80
DOI 10.1038/nrgastro.2016.51, PubMed 27095655
Mapping Protein-DNA Interactions Using ChIP-exo and Illumina-Based Sequencing
Methods Mol Biol, 1443, 119-37
DOI 10.1007/978-1-4939-3724-0_8, PubMed 27246337
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer
Oncotarget, 7 (6), 6476-505
DOI 10.18632/oncotarget.6390, PubMed 26623728
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Lancet Gastroenterol Hepatol, 1 (3), 207-216
DOI 10.1016/S2468-1253(16)30014-0, PubMed 28404093
CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions
Nucleic Acids Res, 44 (22), 10588-10602
DOI 10.1093/nar/gkw785, PubMed 27638884
Mitotic cells form actin-based bridges with adjacent cells to provide intercellular communication during rounding
Cell Cycle, 15 (21), 2943-2957
DOI 10.1080/15384101.2016.1231280, PubMed 27625181
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Tumour Biol, 37 (8), 10697-702
DOI 10.1007/s13277-016-4940-2, PubMed 26867771
Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma
Oncol Rep, 35 (6), 3265-74
DOI 10.3892/or.2016.4765, PubMed 27108527
Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2
Biochem Biophys Res Commun, 476 (2), 102-7
DOI 10.1016/j.bbrc.2016.05.045, PubMed 27178209
Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism
Oncotarget, 7 (11), 12464-76
DOI 10.18632/oncotarget.7039, PubMed 26824323
Regulation of connexins by the ubiquitin system: Implications for intercellular communication and cancer
Biochim Biophys Acta, 1865 (2), 133-46
DOI 10.1016/j.bbcan.2016.02.001, PubMed 26855059
Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
Oncotarget, 7 (5), 5273-88
DOI 10.18632/oncotarget.6567, PubMed 26672768
The importance of DNA methylation in prostate cancer development
J Steroid Biochem Mol Biol, 166, 1-15
DOI 10.1016/j.jsbmb.2016.04.009, PubMed 27117390
Cell cycle-coupled expansion of AR activity promotes cancer progression
Oncogene, 36 (12), 1655-1668
DOI 10.1038/onc.2016.334, PubMed 27669432
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
Urol Oncol, 35 (3), 111.e1-111.e8
DOI 10.1016/j.urolonc.2016.10.002, PubMed 27838142
The role of glycans in the development and progression of prostate cancer
Nat Rev Urol, 13 (6), 324-33
DOI 10.1038/nrurol.2016.65, PubMed 27091662
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability
EBioMedicine, 8, 103-116
DOI 10.1016/j.ebiom.2016.04.018, PubMed 27428423
Experimental factors affecting the robustness of DNA methylation analysis
Sci Rep, 6, 33936
DOI 10.1038/srep33936, PubMed 27671843
Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1
Cancer Lett, 385, 150-159
DOI 10.1016/j.canlet.2016.10.028, PubMed 27984115
PBX3 is a putative biomarker of aggressive prostate cancer
Int J Cancer, 139 (8), 1810-20
DOI 10.1002/ijc.30220, PubMed 27273830
HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer
Oncotarget, 7 (46), 74734-74746
DOI 10.18632/oncotarget.12543, PubMed 27732966
Bilateral ovarian carcinomas differ in the expression of metastasis-related genes
Oncol Lett, 13 (1), 184-190
DOI 10.3892/ol.2016.5384, PubMed 28123539
Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
PLoS Genet, 12 (7), e1006225
DOI 10.1371/journal.pgen.1006225, PubMed 27472274
Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells
Epigenetics Chromatin, 9, 21
DOI 10.1186/s13072-016-0070-8, PubMed 27252783
Gene regulatory mechanisms underpinning prostate cancer susceptibility
Nat Genet, 48 (4), 387-97
DOI 10.1038/ng.3523, PubMed 26950096